JPRN-jRCT2080222838未知1 期
Macitentan Phase 1 study in Japanese healthy male subjects (clinical pharmacokinetics study)
Actelion Pharmaceuticals Japan Ltd.0 个研究点目标入组 16 人开始时间: 2015年4月28日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 50age old（—）
- 性别
- Male
入选标准
- •Signed and dated written informed consent prior to enrollment in the study
- •Healthy Japanese adult males
- •Body mass index (BMI) ≥ 18 and ≤ 28 kg/m2 at screening. BMI = weight (kg) / [height (m)]2
排除标准
- 未提供
研究者
相似试验
未知
1 期
A single-dose study in healthy Japanese male adults to evalaute pharmacokinetics and pharmacodynamics of E5501 5 mg tabletHealthy adultJPRN-jRCT2080222024Eisai Co., Ltd.15
已完成
1 期
A Phase I Study of TR-012001 in Healthy Japanese Adult MalesParkinson's DiseaseJPRN-jRCT2031210658Kanazashi Shuichi21
已完成
2 期
Japanese phase II study in untreated patients with CD20 positive B-cell non-Hodgkin's lymphoma evaluating safety of 90-minute infusion of rituximab.CD20 positive follicular lymphoma or diffuse large B-cell lymphoma.JPRN-jRCT2080223607ZENYAKU KOGYO CO., LTD.33
已完成
不适用
A phase 0 validation study in healthy male volunteers assessing the safety and tolerability of serial CSF sampling and to evaluate biomarkers related to Alzheimer*s disease in CSF and plasmaAlzheimer10029305NL-OMON36095QPS Netherlands B.V.8
未知
1 期
A Two-Part Study in Japanese Patients With Advanced or Metastatic NSCLC. Open-Label Phase I to Assess the Safety & Tolerability of AZD2171 in Combination With Pac/Carb, Then a Phase II, Randomised, Double-Blind Study to Assess the Efficacy of AZD2171 Alone and in Combination With AZD2171 and Pac/CarbCarcinoma, Non-Small-Cell LungJPRN-jRCT2080220478AstraZeneca